Aimed at blocking the estrogen proliferative effect on tumor cells, endocrine therapy, such as selective ER modulator (tamoxifen) and aromatase inhibitors (e.g., anastrozole, letrozole, exemestane), represents the cornerstone of therapy for HR+ and HER2− BC [20,21]. Here, HR is linked to breast cancer.